OBJECTIVE: By a randomised, double-blind, placebo-controlled trial of aciclovir 800 mg twice daily for 5 days added to the syndromic management of genital ulcer disease (GUD) to determine the impact on ulcer healing and HIV outcomes. METHODS:Patients presenting with GUD in Malawi were evaluated for HIV and herpes simplex virus type-2 (HSV-2) serologies, ulcer aetiology, lesional, genital and plasmaHIV-1 RNA and CD4+ count. Patients were followed up at days 2, 4, 7, 14 and 28. The primary study outcome was ulcer healing at day 14, with secondary outcomes being lesional and genital HIV-1 shedding at day 14 and HIV-1 plasma viral load at day 28 among HIV-1/HSV-2 co-infected individuals. RESULTS:Four hundred and twenty-two patients (74% male) were randomised (208 to aciclovir, 214 to placebo), of whom 61% were HIV-1 seropositive and 72% HSV-2 seropositive; 67% (267/398) had HSV-2 ulcers. 85% of ulcers were healed at day 14 with no difference between treatment arms (risk ratio (RR)=1.02, 95% CI 0.93 to 1.11). Among 244 HIV-1/HSV-2 co-infected individuals, aciclovir reduced lesional HIV-1 RNA (adjusted RR=0.64, 95% CI 0.41 to 0.99) and seminal HIV-1 RNA (adjusted RR=0.59, 95% CI 0.40 to 0.88), but not cervical HIV-1 RNA or plasma HIV-1 RNA. CONCLUSIONS: Episodic HSV treatment with aciclovir added to syndromic management did not produce a significant clinical benefit in this African population.
RCT Entities:
OBJECTIVE: By a randomised, double-blind, placebo-controlled trial of aciclovir 800 mg twice daily for 5 days added to the syndromic management of genital ulcer disease (GUD) to determine the impact on ulcer healing and HIV outcomes. METHODS:Patients presenting with GUD in Malawi were evaluated for HIV and herpes simplex virus type-2 (HSV-2) serologies, ulcer aetiology, lesional, genital and plasma HIV-1 RNA and CD4+ count. Patients were followed up at days 2, 4, 7, 14 and 28. The primary study outcome was ulcer healing at day 14, with secondary outcomes being lesional and genital HIV-1 shedding at day 14 and HIV-1 plasma viral load at day 28 among HIV-1/HSV-2 co-infected individuals. RESULTS: Four hundred and twenty-two patients (74% male) were randomised (208 to aciclovir, 214 to placebo), of whom 61% were HIV-1 seropositive and 72% HSV-2 seropositive; 67% (267/398) had HSV-2 ulcers. 85% of ulcers were healed at day 14 with no difference between treatment arms (risk ratio (RR)=1.02, 95% CI 0.93 to 1.11). Among 244 HIV-1/HSV-2 co-infected individuals, aciclovir reduced lesional HIV-1 RNA (adjusted RR=0.64, 95% CI 0.41 to 0.99) and seminal HIV-1 RNA (adjusted RR=0.59, 95% CI 0.40 to 0.88), but not cervical HIV-1 RNA or plasma HIV-1 RNA. CONCLUSIONS: Episodic HSV treatment with aciclovir added to syndromic management did not produce a significant clinical benefit in this African population.
Authors: Jared M Baeten; Stewart E Reid; Sinead Delany-Moretlwe; James P Hughes; Richard S Wang; Ellen Wilcox; Mohammed Limbada; Godspower Akpomiemie; Lawrence Corey; Anna Wald; Connie Celum Journal: Sex Transm Dis Date: 2012-01 Impact factor: 2.830
Authors: Isabelle Leduc; William G Fusco; Neelima Choudhary; Patty A Routh; Deborah M Cholon; Marcia M Hobbs; Glen W Almond; Paul E Orndorff; Christopher Elkins Journal: Infect Immun Date: 2011-06-06 Impact factor: 3.441
Authors: Clare Tanton; Helen A Weiss; Jerome Le Goff; John Changalucha; Mary Rusizoka; Kathy Baisley; Dean Everett; David A Ross; Laurent Belec; Richard J Hayes; Deborah Watson-Jones Journal: PLoS One Date: 2011-03-01 Impact factor: 3.240
Authors: Helen A Weiss; Gabriela Paz Bailey; Sam Phiri; Gerard Gresenguet; Jerome LeGoff; Jacques Pepin; David A Lewis; Laurent Belec; Irving F Hoffman; William C Miller; Philippe Mayaud Journal: PLoS One Date: 2011-07-25 Impact factor: 3.240
Authors: Clare Tanton; Helen A Weiss; Jerome LeGoff; John Changalucha; Tim C Clayton; David A Ross; Laurent Belec; Richard J Hayes; Deborah Watson-Jones Journal: Sex Transm Infect Date: 2011-06-08 Impact factor: 3.519
Authors: J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann Journal: Infection Date: 2013-09-14 Impact factor: 3.553